List of Excipients in Branded Drug EBGLYSS

EBGLYSS Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

EBGLYSS (lebrikizumab-lbkz) is a subcutaneous interleukin-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis. Its commercial formulation uses a conventional biologic excipient system: histidine for pH control, arginine hydrochloride for protein solubility and stabilization, polysorbate 20 for interfacial protection, and water for injection.[1] The strongest commercial opportunities are in high-purity excipient supply, container-closure compatibility, self-injection devices, formulation analytics, biosimilar development, and cold-chain optimization.

What excipients are used in EBGLYSS?

The marketed EBGLYSS formulation is a sterile, preservative-free solution containing 125 mg/mL of lebrikizumab-lbkz. The United States product is supplied as a 250 mg dose in 2 mL, delivered through a single-dose prefilled syringe or autoinjector.[1]

Formulation component	Function	Commercial relevance
L-histidine	Buffer and pH control	Requires biopharmaceutical-grade supply and low impurity burden
Arginine hydrochloride	Solubility enhancement and aggregation control	Relevant to high-concentration antibody stability
Polysorbate 20	Surfactant; limits adsorption and interfacial aggregation	High-value excipient with oxidation and peroxide-control requirements
Water for injection	Solvent	Requires pharmaceutical water-system compliance
Lebrikizumab-lbkz	Anti-IL-13 monoclonal antibody	The active biologic and primary stability driver

Public product information identifies the formulation excipients but does not disclose a complete commercial manufacturing process, excipient supplier list, or proprietary concentration ranges beyond the approved product information.[1,2]

Why does the formulation use arginine hydrochloride?

Arginine hydrochloride is commonly used in antibody formulations to reduce self-association, viscosity, and aggregation. It can improve manufacturability and liquid stability when a protein is prone to reversible oligomerization or concentration-dependent instability.

For EBGLYSS, arginine is commercially important because the product is supplied as a relatively concentrated liquid injection. The excipient may support:

• Reduced protein-protein interaction
• Lower visible and subvisible particle formation
• Improved syringeability
• Better stability during transport and handling
• Reduced dependence on lyophilization

Arginine is not a substitute for a full stability program. Its effect depends on pH, ionic strength, antibody concentration, surfactant condition, container surface, and freeze-thaw exposure.

What role does polysorbate 20 play?

Polysorbate 20 protects the antibody from adsorption to glass, elastomer, siliconized surfaces, and air-liquid interfaces. It also reduces agitation-induced aggregation during shipping and administration.

Polysorbate 20 creates a separate quality-control opportunity because degradation can generate free fatty acids, particulates, and peroxide-related impurities. These degradants can affect antibody oxidation and particle formation. Suppliers and CDMOs that provide low-peroxide, low-particulate polysorbate 20 with strong lot-to-lot consistency have a competitive position in antibody manufacturing.

What is the EBGLYSS formulation strategy?

EBGLYSS uses a liquid, ready-to-inject formulation rather than a lyophilized product. This strategy reduces preparation steps and aligns with home administration through a prefilled syringe or autoinjector.[1]

The formulation strategy has four commercial objectives:

1. Maintain antibody potency and structural integrity during refrigerated storage.
2. Support a 2 mL single-dose presentation.
3. Permit administration by healthcare professionals or patients and caregivers.
4. Avoid reconstitution and minimize dosing friction.

The main technical risks are aggregation, oxidation, particulate formation, viscosity, surfactant degradation, and interaction with the primary container.

Which quality attributes are most important?

A commercial EBGLYSS-type formulation requires control of:

• Monomer content and aggregate profile
• Binding activity against IL-13
• Charge variants
• Oxidation and deamidation
• Subvisible and visible particles
• Polysorbate degradation
• Extractables and leachables
• Container-closure integrity
• Delivered volume and injection force
• Freeze-thaw and agitation stability

The excipient system should be evaluated with orthogonal analytical methods, including size-exclusion chromatography, light obscuration, micro-flow imaging, subvisible particle testing, peptide mapping, potency assays, and surfactant degradation assays.

What commercial opportunities exist for EBGLYSS excipients?

The largest opportunities are not likely to come from selling commodity histidine or arginine alone. Value is concentrated in qualified, low-impurity, biologics-grade materials and in services that reduce formulation and regulatory risk.

High-purity histidine and arginine supply

Excipient suppliers can compete on:

• Endotoxin control
• Elemental impurities
• Bioburden
• Residual solvents
• Lot consistency
• Supply continuity
• Change-control discipline
• DMF or equivalent regulatory support

A supplier with a qualified manufacturing site and established biologics customers has an advantage over a low-cost commodity producer. Switching excipient suppliers late in development can trigger comparability work, stability studies, and regulatory review.

Polysorbate 20 impurity-control platforms

Polysorbate 20 is the most technically differentiated excipient in this formulation. Opportunities include:

• Low-peroxide grades
• Defined fatty-acid distribution
• Improved hydrolytic stability
• Low-particulate grades
• Analytical assays for degradation products
• Stabilized surfactant systems
• Supplier-managed inventory for commercial biologics

The preferred supplier is likely to be evaluated not only on price but on control of peroxide value, free fatty acids, residual solvents, trace metals, and degradation behavior during storage.

Excipient quality-by-design services

Specialized formulation companies can offer design and testing packages that model:

• Protein-excipient interactions
• Agitation and shipping stress
• Freeze-thaw excursions
• Syringe and autoinjector compatibility
• Silicone oil interaction
• Needle gauge effects
• Injection-force performance
• Extractables and leachables

These services can support both originator lifecycle management and biosimilar development.

How do the prefilled syringe and autoinjector affect excipient strategy?

The delivery system affects the acceptable formulation window. A formulation that is stable in a vial may perform differently in a prefilled syringe because of silicone oil, tungsten residues, elastomer contact, headspace, and greater surface-area exposure.

Prefilled syringe considerations

A prefilled syringe requires evaluation of:

• Plunger break-loose and glide force
• Needle shield compatibility
• Silicone-oil levels
• Protein adsorption
• Delivered volume
• Container-closure integrity
• Storage orientation
• Particulate formation

Autoinjector considerations

An autoinjector adds:

• Injection-speed stress
• Device-material contact
• Human-factors requirements
• Needle penetration and dwell time
• Risk of incomplete dose delivery
• Temperature-dependent injection force

The commercial opportunity for device suppliers is strongest where they can provide an integrated combination of container, elastomer, needle, autoinjector, and compatibility data. Device substitution can require bridging studies and regulatory justification even when the drug formulation remains unchanged.

What is the FDA regulatory status of EBGLYSS?

The FDA approved EBGLYSS on September 13, 2024, for moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.[1]

Regulatory item	Status
Active ingredient	Lebrikizumab-lbkz
Target	Interleukin-13
Dosage form	Sterile subcutaneous injection
Strength	250 mg/2 mL
U.S. approval date	September 13, 2024
Initial dosing	500 mg at weeks 0 and 2
Maintenance dosing	250 mg every 2 weeks through week 16, then 250 mg every 4 weeks in responders
U.S. sponsor	Eli Lilly and Company
Development/commercial partner	Almirall has commercial rights in several markets outside the United States
Biosimilar pathway	351(k) under the Public Health Service Act

The European Commission authorized lebrikizumab for eligible atopic dermatitis patients in 2023, with commercial activity conducted by Almirall in designated territories.[2]

When does EBGLYSS lose exclusivity?

EBGLYSS receives biologic reference-product exclusivity under the Public Health Service Act rather than the small-molecule exclusivity framework used for conventional drugs. The 12-year reference-product exclusivity period generally runs from first licensure of the reference product. On the September 13, 2024 U.S. approval date, the statutory reference-product exclusivity period would generally extend to September 13, 2036, subject to the legal treatment of first licensure, pediatric exclusivity, patent litigation, and FDA approval timing.[3]

A biosimilar applicant may file an abbreviated application after the statutory filing restriction expires, but approval and market entry depend on the regulatory pathway, patent litigation, settlement terms, and any applicable exclusivity extensions.

The European timing is jurisdiction-specific. Patent term, supplementary protection certificates, pediatric extensions, and national enforcement can create different entry dates across European markets.

What patents protect EBGLYSS?

The relevant patent estate is likely to include several layers:

• Antibody composition and sequence patents
• Binding-site or epitope patents
• Antibody engineering patents
• Formulation patents
• Treatment patents for atopic dermatitis
• Dosing-regimen patents
• Manufacturing and cell-line patents
• Device or container patents
• Regional divisionals and continuation applications

EBGLYSS is a biologic, so it does not have the same Orange Book listing structure as a conventional small-molecule drug. The relevant U.S. regulatory and patent framework is the Purple Book and the biologic patent-exchange provisions of the Biologics Price Competition and Innovation Act.[3,4]

A complete freedom-to-operate analysis requires claim-level review of issued patents, pending continuations, terminal disclaimers, prosecution history, and jurisdiction-specific legal status. Public product labeling alone does not establish which formulation or manufacturing claims remain enforceable.

Are formulation patents commercially important?

Yes. A formulation patent can protect the selected buffer, amino acid, surfactant, pH range, concentration range, or stability profile even when the antibody sequence patent is approaching expiry.

For EBGLYSS, the strongest formulation claims would likely require a combination of:

• Lebrikizumab or a defined antibody sequence
• Histidine buffer
• Arginine hydrochloride
• Polysorbate 20
• Defined pH and concentration ranges
• Specified stability or aggregation limits

Broad claims covering common antibody excipients may face validity and prior-art challenges. Narrow claims tied to a particular antibody, concentration, pH range, device, or stability result can provide stronger product-specific protection.

What Paragraph IV or biosimilar challenges affect EBGLYSS?

EBGLYSS is a biologic, so the principal competitive challenge will be a 351(k) biosimilar application rather than a Hatch-Waxman Paragraph IV certification. The biosimilar applicant must demonstrate high similarity to the reference product and address interchangeability if seeking that designation.[3]

Potential biosimilar challenges include:

• Antibody sequence and higher-order structure
• Glycosylation and charge variants
• Potency and receptor-binding assays
• Formulation similarity
• Container-closure differences
• Prefilled syringe or autoinjector presentation
• Manufacturing-cell-line and process differences
• Patent litigation under the BPCIA

A biosimilar does not necessarily need to use identical excipient concentrations or the same device. Differences must be justified through analytical, clinical, and device-comparability data.

How does EBGLYSS compare with competing atopic dermatitis biologics?

EBGLYSS competes primarily with Dupixent (dupilumab), Adbry (tralokinumab-ldrm), and oral Janus kinase inhibitors. The principal differentiation is selective IL-13 blockade, dosing convenience after the induction period, and the potential for use in patients who prefer a biologic over oral immunosuppression.[1,5]

Product	Mechanism	Delivery	Excipient opportunity
EBGLYSS	IL-13 antibody	Prefilled syringe/autoinjector	Histidine, arginine hydrochloride, polysorbate 20, device compatibility
Dupixent	IL-4 receptor alpha antibody	Prefilled syringe/autoinjector	Competing high-volume biologic supply and device ecosystem
Adbry	IL-13 antibody	Prefilled syringe	Similar target class; formulation and biosimilar overlap
JAK inhibitors	Small-molecule pathway inhibition	Oral	Different formulation, manufacturing, and generic-entry economics

EBGLYSS and Adbry create the closest mechanism-based comparison. Their commercial competition will depend on efficacy, dosing interval, safety labeling, payer access, physician familiarity, and device usability, not only on excipient composition.

What generic launch risks exist?

Traditional generic entry is not the primary risk because EBGLYSS is a monoclonal antibody. The relevant entry risks are:

1. Biosimilar development after reference-product exclusivity restrictions expire.
2. Patent litigation involving antibody sequence, formulation, use, or manufacturing claims.
3. Follow-on products with alternative injection devices.
4. Competing IL-13 antibodies.
5. Combination or topical products that reduce demand for injectable therapy.
6. Payer-driven switching between biologics.

The formulation creates a moderate barrier because a biosimilar developer must reproduce critical quality attributes and demonstrate acceptable stability in its own manufacturing system. The barrier is lower where excipients are standard, commercially available, and not protected by narrow formulation claims.

What licensing and manufacturing opportunities exist?

Almirall’s role in lebrikizumab commercialization demonstrates the value of regional licensing for specialty biologics. Territory-specific commercial rights can support market access, medical affairs, reimbursement, and dermatology distribution without requiring one company to build a global commercial infrastructure.[2]

Manufacturing opportunities include:

• Mammalian-cell culture and downstream purification
• Drug-substance fill-finish
• Prefilled syringe assembly
• Autoinjector integration
• Stability and release testing
• Cold-chain logistics
• Biosimilar analytical comparability
• Excipient sourcing and qualification

The most defensible suppliers will combine regulatory documentation with operational reliability. For a commercial antibody, an excipient change can create more cost through comparability and stability work than the excipient itself represents in the bill of materials.

How strong is the EBGLYSS excipient position?

The excipient position is technically credible but not inherently difficult to replicate. Histidine, arginine hydrochloride, polysorbate 20, and water for injection are established biologic formulation components. The stronger barriers are likely to arise from the interaction of the excipient system with:

• The specific lebrikizumab molecule
• The 125 mg/mL concentration
• The primary container
• The delivery device
• The manufacturing process
• The stability specification
• Any patent claims limited to the product combination

Commercial strength therefore depends more on qualification, analytical control, device integration, and regulatory history than on excipient scarcity.

Key Takeaways

• EBGLYSS uses a conventional but commercially effective antibody formulation based on histidine, arginine hydrochloride, polysorbate 20, and water for injection.
• Polysorbate 20 control is the most technically sensitive excipient opportunity because oxidation, hydrolysis, particles, and peroxide impurities can affect antibody quality.
• Arginine hydrochloride supports concentrated liquid formulation and may improve aggregation and viscosity performance.
• The prefilled syringe and autoinjector create additional opportunities in container compatibility, device integration, injection-force testing, and extractables and leachables.
• EBGLYSS was FDA-approved on September 13, 2024, and generally benefits from 12 years of U.S. reference-product biologic exclusivity, subject to statutory and patent considerations.
• Biosimilar competition, rather than conventional Paragraph IV generic entry, is the primary long-term challenge.
• The formulation is reproducible in principle, but product-specific stability data, device qualification, manufacturing history, and formulation or process patents can raise entry costs.
• High-value commercial opportunities are concentrated in qualified excipient supply, polysorbate analytics, biologic formulation services, fill-finish, device systems, and biosimilar comparability.

FAQs

What is the main excipient opportunity for EBGLYSS suppliers?

Polysorbate 20 with strong control of peroxide value, free fatty acids, particulates, and lot-to-lot degradation behavior offers the most differentiated opportunity.

Can a biosimilar use different excipients from EBGLYSS?

Yes. A biosimilar may use a different excipient system if it demonstrates sufficient analytical, clinical, stability, and regulatory comparability.

Is EBGLYSS listed in the Orange Book?

No. EBGLYSS is a biologic. Its relevant U.S. regulatory framework is the Purple Book and the BPCIA rather than the conventional Orange Book pathway.

Does EBGLYSS require cold-chain distribution?

Commercial monoclonal antibody products generally require controlled refrigerated storage. Temperature excursions, freezing, agitation, and light exposure must be evaluated against the approved product conditions.[1]

Which formulation parameter is most likely to affect device performance?

Viscosity and interfacial stability are central. They influence injection force, dose delivery, aggregation, and compatibility with the syringe, needle, elastomer, and autoinjector.

References

1. U.S. Food and Drug Administration. (2024). EBGLYSS (lebrikizumab-lbkz) prescribing information. Eli Lilly and Company.

2. European Medicines Agency. (2023). Ebglyss: EPAR - product information. European Union.

3. U.S. Food and Drug Administration. (2024). Implementation of the Biologics Price Competition and Innovation Act of 2009. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Dupixent and Adbry prescribing information. U.S. Department of Health and Human Services.